Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors
Overview
Authors
Affiliations
Monoclonal antibodies targeting the PD-1/PD-L1 immune checkpoint have considerably improved the treatment of some cancers, but novel drugs, new combinations, and treatment modalities are needed to reinvigorate immunosurveillance in immune-refractory tumors. An option to elicit antitumor immunity against cancer consists of using approved and marketed drugs known for their capacity to modulate the expression and functioning of the PD-1/PD-L1 checkpoint. Here, we have reviewed several types of drugs known to alter the checkpoint, either directly via the blockade of PD-L1 or indirectly via an action on upstream effectors (such as STAT3) to suppress PD-L1 transcription or to induce its proteasomal degradation. Specifically, the repositioning of the approved drugs liothyronine, azelnidipine (and related dihydropyridine calcium channel blockers), niclosamide, albendazole/flubendazole, and a few other modulators of the PD-1/PD-L1 checkpoint (repaglinide, pimozide, fenofibrate, lonazolac, propranolol) is presented. Their capacity to bind to PD-L1 or to repress its expression and function offer novel perspectives for combination with PD-1 targeted biotherapeutics. These known and affordable drugs could be useful to improve the therapy of cancer.
Application of Nanotechnology and Phytochemicals in Anticancer Therapy.
Kim J, Dareowolabi B, Thiruvengadam R, Moon E Pharmaceutics. 2024; 16(9).
PMID: 39339205 PMC: 11435124. DOI: 10.3390/pharmaceutics16091169.
The Neuroimmune Axis and Its Therapeutic Potential for Primary Liver Cancer.
Mandal S, Yadav P, Sheth R Int J Mol Sci. 2024; 25(11).
PMID: 38892423 PMC: 11172507. DOI: 10.3390/ijms25116237.
Xia W, Zheng X, Liu W, Huang Y, Wen C, Zhou H Cancer Gene Ther. 2024; 31(5):778-789.
PMID: 38480975 DOI: 10.1038/s41417-024-00760-0.
Karnik I, Her Z, Neo S, Liu W, Chen Q Pharmaceutics. 2023; 15(6).
PMID: 37376049 PMC: 10305679. DOI: 10.3390/pharmaceutics15061600.